13F Holdings
中文EN

CRLBF Cresco Labs Inc. Annual reports only

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1832928 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-9.5%
TTM net income YoY-81.9%
TTM EPS YoY-72.7%
Revenue 3-yr CAGR-8.0%
Net income 3-yr CAGR—

Margins

Gross margin49.5%
Operating margin-4.3%
Net margin-20.6%
FCF margin5.8%
EBITDA margin3.2%

Returns

ROE-33.2%
ROA-10.6%
ROIC (approx.)-2.9%
Asset turnover0.51x

Leverage & solvency

Liabilities / assets78.9%
Debt / equity1.23x
Current ratio2.59x
Interest coverage-0.67x

Cash quality & payout

Operating cash flow / net income-0.54x
Accruals ratio-16.3%
Payout ratio—
Capex / revenue5.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$655.85M$724.34M$770.88M$842.68M$821.68M
Cost of revenue$331.28M$359.89M$408.52M$435.67M$415.33M
Gross profit$324.57M$364.45M$362.37M$407.01M$406.35M
SG&A expense$247.45M$254.84M$299.17M$350.65M$317.80M
Operating income-$27.99M$107.29M-$87.82M-$84.30M-$217.35M
Interest expense$41.75M$37.93M$43.58M$57.84M$51.21M
Pretax income-$95.42M-$10.62M-$146.90M-$126.91M-$256.73M
Income tax$44.62M$49.87M$32.95M$88.94M$40.11M
Net income-$135.41M-$74.44M-$175.52M-$212.05M-$319.60M
EBITDA$20.73M$166.39M-$25.31M-$32.37M-$178.71M
EPS (basic)-0.38-0.22-0.54-0.71-1.22
EPS (diluted)-0.38-0.22-0.54-0.71-1.22
Weighted avg. shares (diluted)355.01M345.47M323.82M298.16M262.33M
Balance sheet
Cash & equivalents$57.90M$137.56M$108.52M$121.51M$223.54M
Receivables$37.89M$51.56M$51.07M$56.49M$43.38M
Inventory$98.67M$83.34M$107.79M$134.61M$136.64M
Current assets$259.27M$294.26M$278.09M$326.05M$421.75M
PP&E, net$327.19M$344.85M$368.31M$379.72M$369.09M
Goodwill$208.17M$283.48M$279.70M$330.56M$446.77M
Intangibles$275.34M$293.99M$296.97M$407.59M$437.64M
Total assets$1.20B$1.36B$1.36B$1.58B$1.78B
Current liabilities$100.18M$94.34M$200.24M$255.87M$288.39M
Short-term debt$3.30M$2.61M$2.00M$10.98M$19.93M
Long-term debt$417.10M$460.75M$497.71M$476.89M$465.08M
Total debt$420.39M$463.36M$499.72M$487.87M$485.01M
Total liabilities$944.80M$967.18M$930.40M$996.01M$982.73M
Shareholders' equity$340.45M$474.85M$505.69M$627.04M$755.55M
Net debt$362.49M$325.80M$391.20M$366.36M$261.46M
Cash flow statement
Operating cash flow$72.89M$132.48M$58.56M$18.74M$14.49M
Capital expenditure$35.14M$19.49M$55.38M$83.03M$93.88M
Free cash flow$37.75M$112.99M$3.18M-$64.28M-$79.39M
Investing cash flow-$40.70M-$25.23M-$44.59M-$36.58M-$163.93M
Financing cash flow-$82.09M-$71.48M-$26.91M-$86.64M$235.00M
Depreciation & amortization$48.71M$59.10M$62.51M$51.93M$38.64M
Stock-based compensation$11.23M$14.16M$16.36M$23.22M$27.54M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.